Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Sep 4 · above the Ichimoku cloud · RSI 69 · MACD above its signal
| 69.00 | 52-week high | +624.79% |
| 10.76 | R3 (classic) | +13.06% |
| 10.12 | R2 (classic) | +6.27% |
| 9.52 | Price now | |
| 9.47 | Previous day high | −0.53% |
| 9.11 | R1 (classic) | −4.27% |
| 8.47 | Pivot | −11.06% |
| 7.96 | Previous week high | −16.42% |
| 7.82 | Previous day low | −17.86% |
| 7.65 | Previous month high | −19.64% |
| 7.46 | S1 (classic) | −21.60% |
| 6.82 | S2 (classic) | −28.40% |
| 6.46 | Previous week low | −32.14% |
| 5.81 | S3 (classic) | −38.94% |
| 5.18 | Previous month low | −45.59% |
| 4.51 | 52-week low | −52.63% |
None of the 29 investors followed here reported a position in RGC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RGC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for RGC.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.0 | 5.0 | -3.0 | 14.9 | -18.2 | -74.5 | 1.5 | -10.8 | 12.9 | 53.1 | −54.7% | ||
| 2025 | -23.1 | 21.1 | 593.0 | 88.2 | 1361.7 | -26.2 | -22.5 | 6.4 | 10.0 | 7.8 | -30.8 | 82.1 | +16053.8% |
| 2024 | -24.7 | -14.7 | -33.3 | 17.1 | -10.8 | -28.5 | 186.6 | -24.9 | -23.3 | 19.0 | -4.2 | -21.8 | −53.0% |
| 2023 | 3.3 | -3.8 | -6.6 | 3.5 | -19.1 | 6.3 | -19.0 | -11.6 | -13.6 | 11.8 | -32.0 | -3.1 | −62.4% |
| 2022 | 9.9 | 3.5 | -40.9 | 4.7 | 34.5 | 14.9 | -7.5 | -4.0 | 3.6 | -13.4 | 12.6 | -10.0 | −12.4% |
| 2021 | 274.6 | -34.1 | -40.7 | 88.0 | 26.1 | +247.3% |
No analyst coverage for this instrument.
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.